Customize View
Named by Company
Named by Competitor
Named by Third Party

Recently disclosed competitors only (within the last two years)
Include Competitors for:Current subsidiaries


Competitors

Recently Disclosed Competitors
Competitor's Name
Company
LTM Revenue ($mm)
LTM Date
Source
Charles River Laboratories International, Inc. (NYSE:CRL)
Medelis, Inc.
4,178.31
Jul-01-2023
Frontage Holdings Corporation (SEHK:1521) - Form Doc
Business Description: Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Frontage Holdings Corporation (SEHK:1521)
Medelis, Inc.
259.78
Jun-30-2023
Frontage Holdings Corporation (SEHK:1521) - Form Doc
Business Description: Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies. It offers laboratory testing services, such as method development and validation, and sample analysis and central laboratory services; chemistry, manufacturing, and control services, including assistance in drug product development and analysis, and delivery and supply of clinical trial materials; and drug metabolism and pharmacokinetic services. The company also provides early stage clinical/bioequivalence services; absolute bioavailability and human radiolabel studies; and chemistry services, including performing custom synthesis. It operates in the United States, the People’s Republic of China, Europe, India, Japan, South Korea, and Australia. The company was incorporated in 2018 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.
ICON Public Limited Company (NasdaqGS:ICLR)
Medelis, Inc.
7,903.26
Jun-30-2023
Frontage Holdings Corporation (SEHK:1521) - Form Doc
Business Description: ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; and clinical research services, including biostatistics, clinical operations, clinical supplies management, covid-19, data management, decentralized & hybrid clinical solutions, endpoint adjudication services, interactive response technologies, investigator payments, medical affairs, medical writing and publishing, pharmacovigilance, and site and patient solutions. The company also provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. In addition, it offers commercial positioning, early phase, language, medical imaging, and strategic solutions, as well as clinical trial management, consulting, and contract staffing services. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
IQVIA Holdings Inc. (NYSE:IQV)
Medelis, Inc.
14,681.00
Jun-30-2023
Frontage Holdings Corporation (SEHK:1521) - Form Doc
Business Description: IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was incorporated in 2016 and is headquartered in Durham, North Carolina.
Laboratory Corporation of America Holdings (NYSE:LH)
Medelis, Inc.
14,880.80
Jun-30-2023
Frontage Holdings Corporation (SEHK:1521) - Form Doc
Business Description: Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications to enable patients to check test results; and online applications for MCOs and accountable care organizations; and end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves MCOs, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
Medpace Holdings, Inc. (NasdaqGS:MEDP)
Medelis, Inc.
1,672.78
Jun-30-2023
Frontage Holdings Corporation (SEHK:1521) - Form Doc
Business Description: Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
PAREXEL International Corporation
Medelis, Inc.
2,117.60
Jun-30-2017
Frontage Holdings Corporation (SEHK:1521) - Form Doc
Business Description: Parexel International Corporation, a biopharmaceutical outsourcing company, provides clinical research and logistics, medical communications, consulting, and technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company offers clinical development, including translational medicine, early phase, phase II-III, phase IIIb/IV, biostatistics, clinical data management, clinical supply chain management, decentralized clinical trials, medical monitoring and consulting, medical writing, patient sensors, pharmacovigilance, and risk-based quality management (RBQM); outsourcing services, including functional services provider (FSP), strategic partnerships, and meeting management and logistics; consulting, including regulatory affairs consulting, clinical development strategy and planning, GxP compliance consulting, regulatory outsourcing, clinical trial regulatory services, market access and HEOR consulting, and commercial strategy (health advances); medical affairs, including the medical affairs company (TMAC), medical communications, and expanded access services; real-world evidence and late phase, including epidemiology, observational studies, and real-world data sciences; industry solutions, including pharma solutions and medical devices; and development phase solutions. Parexel International Corporation has strategic agreements with Microsoft Corporation; Synairgen plc; and CTC North GmbH & Co. KG. The company was incorporated in 1983 and is based in Newton, Massachusetts, with branches in Waltham and Billerica, Massachusetts and Uxbridge, United Kingdom. It has additional locations throughout the world.
Pharmaceutical Product Development, LLC
Medelis, Inc.
1,594.81
Sep-30-2011
Frontage Holdings Corporation (SEHK:1521) - Form Doc
Business Description: Pharmaceutical Product Development, LLC, a contract research organization, provides drug development, laboratory, and lifecycle management services to pharmaceutical, biotechnology, medical device, academic, and government organizations worldwide. It offers nonclinical pharmacology/toxicology development and chemistry, manufacturing, and controls consulting services; and clinical development services, which include project management, site intelligence and activation, clinical trial monitoring, data, and analytics platform, data management, biostatistics, pharmacovigilance, functional service, regulatory affairs, quality, and compliance, IVR/IWR system services, clinical supplies, and clinical trial capabilities. The company also provides post-approval studies and late-stage research services, such as early planning, medical communications, medical writing, late-stage research, research coordination center, registries and observational studies, real-world outcomes, risk management, and REMS; consulting services, which include product development, biosimilar development, adaptive trial design, pediatrics, rare diseases, cardiovascular outcomes, global quality and compliance, and medical devices; and technology products and services development, learning development and training, business process and change management, and global technology services. It has strategic alliances with NeoGenomics, Inc. and Harbour BioMed. Pharmaceutical Product Development, LLC was founded in 1985 and is based in Wilmington, North Carolina, with additional offices worldwide. Pharmaceutical Product Development, LLC operates as a subsidiary of Wildcat Acquisition Holdings (UK) Limited.
Syneos Health, Inc.
Medelis, Inc.
5,418.97
Jun-30-2023
Frontage Holdings Corporation (SEHK:1521) - Form Doc
Business Description: Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. As of September 28, 2023, Syneos Health, Inc. was taken private.
*denotes proprietary relationship